James Dentzer
Chief Executive Officer chez CURIS, INC.
Fortune : 59 698 $ au 31/03/2024
Profil
James E.
Dentzer is currently the President, Chief Executive Officer & Director at Curis, Inc. and an Independent Director at Imunon, Inc. He previously held positions as the Chief Financial Officer-DuPont Flooring Systems at EIDP, Inc., Controller at Biogen, Inc., Chief Financial Officer at Amicus Therapeutics, Inc., Chief Financial Officer at Dicerna Pharmaceuticals, Inc., and Chief Financial Officer at Valeritas, Inc. Mr. Dentzer obtained his undergraduate degree from Boston College and his MBA from The University of Chicago Booth School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CURIS, INC.
0,09% | 31/07/2023 | 5 492 ( 0,09% ) | 59 698 $ | 31/03/2024 |
IMUNON, INC.
-.--% | 26/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de James Dentzer
| Sociétés | Poste | Début |
|---|---|---|
| CURIS, INC. | Chief Executive Officer | 24/09/2018 |
| IMUNON, INC. | Director/Board Member | 03/10/2022 |
Anciens postes connus de James Dentzer
| Sociétés | Poste | Fin |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Director of Finance/CFO | 15/12/2015 |
| VALERITAS INC | Director of Finance/CFO | 01/12/2013 |
| AMICUS THERAPEUTICS, INC. | Director of Finance/CFO | 29/10/2009 |
| BIOGEN INC. | Comptroller/Controller/Auditor | - |
| E I DU PONT DE NEMOURS AND CO | Corporate Officer/Principal | - |
Formation de James Dentzer
| Boston College | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BIOGEN INC. | Health Technology |
| IMUNON, INC. | Health Technology |
| CURIS, INC. | Health Technology |
| AMICUS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN. | Process Industries |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
Valeritas, Inc.
 Valeritas, Inc. Medical SpecialtiesHealth Technology Valeritas, Inc. engages in the development and commercialization of drug delivery solutions for the treatment of diabetes. Its product, V-Go wearable insulin delivery device, which enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery by using one type of insulin at a continuous preset basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. The company was founded on August 2, 2006 and is headquartered in Bridgewater, NJ. | Health Technology |
